TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23856172

Group type: EXPERIMENTAL
Intervention: C+L+ (Caffeine 200mg + Bright light 10,000 lux)
Number of subjects: 12

Group type: COMPARATOR
Intervention: C‐L‐ (Caffeine placebo + Bright light placebo <50 lux)
Number of subjects: 12
Study: 22235509

Group type: EXPERIMENTAL
Intervention: Lavender essence
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clinically neutral aromatic material (control)
Number of subjects: 200
Study: 19317898

Group type: EXPERIMENTAL
Intervention: Dignity Therapy offered in addition to standard care
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 64
Study: 16681811

Group type: EXPERIMENTAL
Intervention: Traditional antimycotic treatment
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Interventions designed to strengthen the patients' immune response
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Psychosocial factors, particularly stress
Number of subjects: 309

Group type: COMPARATOR
Intervention: Somatic factors
Number of subjects: 309
Study: 15058351

Group type: EXPERIMENTAL
Intervention: 150 dB/octave slope
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4800 dB/octave slope
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 75 dB presentation level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 45 dB presentation level
Number of subjects: 0
Study: 11044758

Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 9446368

Group type: EXPERIMENTAL
Intervention: Excision with upper esophageal sphincter myotomy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Diverticulopexy with upper esophageal sphincter myotomy
Number of subjects: 39
Study: 8405018

Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible (50 mg)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 3806488

Group type: EXPERIMENTAL
Intervention: Established treatment for hypertension interrupted by placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High score group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low score group
Number of subjects: 0
Study: 31081595

Group type: EXPERIMENTAL
Intervention: Immediate allopurinol dose escalation to SU target
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional dosing for 1 year followed by dose escalation to target (Control)
Number of subjects: 87
Study: 29210625

Group type: EXPERIMENTAL
Intervention: Serum-derived bovine immunoglobulin/protein isolate (SBI) at 2.5 or 5.0 g BID for 4 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Serum-derived bovine immunoglobulin/protein isolate (SBI) at 2.5 or 5.0 g BID
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 103
Study: 26612545

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg
Number of subjects: 5169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5169

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 5169
Study: 24050581

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Music during kangaroo care (KC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 22035351

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19501752

Group type: EXPERIMENTAL
Intervention: Fibre and health information on the product
Number of subjects: 0

Group type: COMPARATOR
Intervention: No health benefit information
Number of subjects: 0
Study: 16768603

Group type: EXPERIMENTAL
Intervention: Stress during consolidation
Number of subjects: 157

Group type: COMPARATOR
Intervention: No stress (control)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Stress during retrieval
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Cortisol measurement
Number of subjects: 157
Study: 12619182

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control
Number of subjects: 170
Study: 11340839

Group type: EXPERIMENTAL
Intervention: Participation in the RCT
Number of subjects: 20
Study: 9735577

Group type: EXPERIMENTAL
Intervention: Pure self-help (PSH)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Guided self-help (GSH)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waiting list (WL) control
Number of subjects: 72
Study: 7999809

Group type: EXPERIMENTAL
Intervention: Intramuscular rHuEpo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Subcutaneous rHuEpo
Number of subjects: 6
Study: 3259732

Group type: EXPERIMENTAL
Intervention: Autotransfusion of drained mediastinal blood
Number of subjects: 25

Group type: COMPARATOR
Intervention: Stored blood
Number of subjects: 25
Study: 29300256

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (5 mL of intraurethral aqueous gel)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 28577105

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 58
Study: 25917337

Group type: EXPERIMENTAL
Intervention: High-rate cut-off VT zone > 200 bpm (arm B)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 60-second delayed therapy in the VT zone 170-199 bpm (arm C)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Prior AT
Number of subjects: 203
Study: 23453785

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 51

Group type: COMPARATOR
Intervention: LRYGB
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: LAGB
Number of subjects: 51
Study: 21985746

Group type: EXPERIMENTAL
Intervention: Caries preventive package (fluoride varnish twice per year for three years, fluoride toothpaste 1,450 ppm F supplied twice per year, toothbrush supplied twice a year, plus standardised dental health education)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standardised dental health education
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Caries preventive package
Number of subjects: 1200
Study: 19935992

Group type: EXPERIMENTAL
Intervention: Percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non‐particulate Betamethasone.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluoroscopically directed caudal epidural steroid injections with local anesthetic, steroids, and 0.9% sodium chloride solution.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Percutaneous adhesiolysis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluoroscopically directed caudal epidural steroid injections
Number of subjects: 120
Study: 16998653

Group type: EXPERIMENTAL
Intervention: Local intra-arterial fibrinolysis (LIF)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 63
Study: 15259905

Group type: EXPERIMENTAL
Intervention: Once-daily saquinavir/ritonavir 1600/100 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Once-daily saquinavir/ritonavir 2000/100 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Twice-daily saquinavir/ritonavir 1000/100 mg
Number of subjects: 18
Study: 10380965

Group type: EXPERIMENTAL
Intervention: Event-related fMRI analysis during number comparison tasks
Number of subjects: 0
Study: 8696719

Group type: EXPERIMENTAL
Intervention: Mitomycin‐navelbine‐cisplatin (MNP)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Mitomycin‐vindesine‐cisplatin (MVP)
Number of subjects: 209
Study: 2060551

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD) 0.8, 1.6, and 3.2 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral prednisolone (PRED) 5, 10, and 20 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Comparison of BUD and PRED
Number of subjects: 12
Study: 6841392

Group type: EXPERIMENTAL
Intervention: Discectomy within 48 hours of myelography (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discectomy at least seven days after myelography (Group 2)
Number of subjects: 0
Study: 31923301

Group type: EXPERIMENTAL
Intervention: Sonic device
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional drills
Number of subjects: 16
Study: 30943934

Group type: EXPERIMENTAL
Intervention: Great Live and Move Challenge (GLMC) intervention delivered over 3.5 months per year for two years.
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 4000
Study: 27544575

Group type: EXPERIMENTAL
Intervention: Titanium clips (group A)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Bipolar coagulation (group B)
Number of subjects: 220
Study: 25467598

Group type: EXPERIMENTAL
Intervention: Breast Feeding (BF)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Music Therapy (MT)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Combined Breast Feeding and Music Therapy (BF+MT)
Number of subjects: 250

Group type: COMPARATOR
Intervention: No Intervention (Control)
Number of subjects: 250
Study: 23837690

Group type: EXPERIMENTAL
Intervention: Go-rei-San (GRS) 7.5 g orally the day before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 100
Study: 21845249

Group type: EXPERIMENTAL
Intervention: Motorized Ridge Expanders (MRE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lateral Ridge Augmentation (LRA)
Number of subjects: 8
Study: 18059031

Group type: EXPERIMENTAL
Intervention: alpha tocopherol (400 IU/day) and beta carotene (30 mg/day) supplements
Number of subjects: 540

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 540
Study: 16814130

Group type: EXPERIMENTAL
Intervention: Patient Empowerment Model (PEM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Compliance-based Model (CEM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Net reduction between PEM and CEM
Number of subjects: 60
Study: 15232810

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium chloride (MgCl2), 50 mmol/24 hours, administered for 36 hours after induction of anesthesia
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 11086757

Group type: EXPERIMENTAL
Intervention: Tape
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Braces
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Shoes
Number of subjects: 8
Study: 8882841

Group type: EXPERIMENTAL
Intervention: Viewing socially stressful situations (Caucasian perpetrator)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Viewing socially stressful situations (Black perpetrator)
Number of subjects: 92
Study: 1370509

Group type: EXPERIMENTAL
Intervention: Opiate exposure (dihydrocodeine, hydrocodone, codeine, morphine)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Opiate exposure
Number of subjects: 39

Group type: COMPARATOR
Intervention: Atopic status (positive cutaneous test results to two or more of nine common aeroallergens)
Number of subjects: 39
Study: 6372855

Group type: EXPERIMENTAL
Intervention: Oral acyclovir for 7 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 31
Study: 3015401

Group type: EXPERIMENTAL
Intervention: Group A (lomustine, cyclophosphamide, vincristine, cisplatin, and doxorubicin monthly)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Group B (five-drug regimen on Months 1, 3, and 5; 5-FU by constant infusion, methotrexate, and mitomycin on Months 2, 4, and 6)
Number of subjects: 47
Study: 29125718

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fasted condition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Overall (all meal conditions)
Number of subjects: 24
Study: 28317362

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticle-labeled group (experimental group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 24315294

Group type: EXPERIMENTAL
Intervention: 1.0% prednisolone sodium phosphate
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 22129231

Group type: EXPERIMENTAL
Intervention: Plastic BioSand Water Filter (BSF)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Control villages
Number of subjects: 1147
Study: 20451538

Group type: EXPERIMENTAL
Intervention: SCT (dairy fats)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MCT (coconut oil)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LCT (beef tallow)
Number of subjects: 18
Study: 17947341

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg q.d.)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 15916709

Group type: EXPERIMENTAL
Intervention: Irvingia gabonensis (IG) 1.05 g three times a day for one month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 40
Study: 12842747

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (GBP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Open gastric bypass (GBP)
Number of subjects: 36
Study: 10381282

Group type: EXPERIMENTAL
Intervention: Longeval subjects (85-102 years)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Seniors (65-75 years)
Number of subjects: 279

Group type: COMPARATOR
Intervention: MTHFR gene mutation
Number of subjects: 279
Study: 8621995

Group type: EXPERIMENTAL
Intervention: Unknown factors associated with carrying a first live birth
Number of subjects: 14948

Group type: EXPERIMENTAL
Intervention: Nulliparity
Number of subjects: 14948

Group type: EXPERIMENTAL
Intervention: Maternal age greater than 30 years
Number of subjects: 14948

Group type: EXPERIMENTAL
Intervention: Positive urine culture
Number of subjects: 14948

Group type: EXPERIMENTAL
Intervention: Women over 150 pounds at the onset of pregnancy
Number of subjects: 14948

Group type: EXPERIMENTAL
Intervention: Prenatal urine protein > or = 2+
Number of subjects: 14948

Group type: EXPERIMENTAL
Intervention: Cigarette smoking during the first trimester
Number of subjects: 14948
Study: 1812901

Group type: EXPERIMENTAL
Intervention: Plax pre-brushing rinse followed by brushing with ADA-approved toothbrush and fluoride toothpaste
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo pre-brushing rinse followed by brushing with ADA-approved toothbrush and fluoride toothpaste
Number of subjects: 19
Study: 6682617

Group type: EXPERIMENTAL
Intervention: Hydralazine (225 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (160 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of Hydralazine and Isosorbide dinitrate (H + I)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (I)
Number of subjects: 49
Study: 31743507

Group type: EXPERIMENTAL
Intervention: Resistance exercise intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Time-matched contact control condition
Number of subjects: 30
Study: 28885231

Group type: EXPERIMENTAL
Intervention: Shortwave diathermy (SWD) in NP(+) group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Shortwave diathermy (SWD) in NP(-) group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham treatment in NP(+) group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham treatment in NP(-) group
Number of subjects: 57
Study: 26486999

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided breast-conserving surgery (USS)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard palpation-guided surgery (PGS)
Number of subjects: 134
Study: 25265449

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 667

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study: 22722664

Group type: EXPERIMENTAL
Intervention: DAWBA disclosed (n = 144)
Number of subjects: 270

Group type: COMPARATOR
Intervention: DAWBA non-disclosed (n = 126)
Number of subjects: 270
Study: 20406686

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sirolimus and Cyclosporine
Number of subjects: 19
Study: 16928779

Group type: EXPERIMENTAL
Intervention: Home-based exercise education intervention program (12 weeks)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 116
Study: 15672849

Group type: EXPERIMENTAL
Intervention: Volume-limited NPPV
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pressure-limited NPPV
Number of subjects: 15
Study: 11585015

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy targeting diastolic dysfunction
Number of subjects: 0
Study: 9143253

Group type: EXPERIMENTAL
Intervention: Live oral polio virus vaccine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7496197

Group type: EXPERIMENTAL
Intervention: Pentamidine therapy at the beginning of the nervous stage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arsobal therapy (2, 16 mg/kg/d for 10 consecutive days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DFMO therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MLD 73811 and IMOL 881
Number of subjects: 0
Study: 2897207

Group type: EXPERIMENTAL
Intervention: Beta-mimetic tocolytic administration
Number of subjects: 890
Study: 31158266

Group type: EXPERIMENTAL
Intervention: Water filters and portable biomass-burning natural draft rocket-style cookstoves
Number of subjects: 1582
Study: 28701336

Group type: EXPERIMENTAL
Intervention: Reframe-IT plus treatment as usual (TAU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reframe-IT plus TAU
Number of subjects: 50
Study: 26565938

Group type: EXPERIMENTAL
Intervention: Dialysate flow (Qd) of 600ml/min
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dialysate flow (Qd) of 700ml/min
Number of subjects: 37

Group type: COMPARATOR
Intervention: Dialysate flow (Qd) of 500ml/min
Number of subjects: 37
Study: 23835112

Group type: EXPERIMENTAL
Intervention: Amlodipine and Olmesartan (A/O)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hydrochlorothiazide and Losartan (L/H)
Number of subjects: 66
Study: 21226640

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19822078

Group type: EXPERIMENTAL
Intervention: rhMCP-1 (0.02-2.0 microg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17343938

Group type: COMPARATOR
Intervention: Conventional radiotherapy at 2 Gy/fraction/day, 5 days/week to 70 Gy/7 weeks
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Split course bifractionated radiotherapy at 1.6 Gy/fraction, twice daily, 5 days/week to 70.4 Gy/6 weeks
Number of subjects: 154
Study: 14998241

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 39
Study: 11913269

Group type: EXPERIMENTAL
Intervention: Vitamin tablet containing seven active ingredients
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 63
Study: 9436668

Group type: EXPERIMENTAL
Intervention: Normegon
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Follegon
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metrodin HP
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normegon, Follegon, Metrodin HP
Number of subjects: 36
Study: 7894117

Group type: EXPERIMENTAL
Intervention: Early radiotherapy (40 Gy in 15 fractions)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Late radiotherapy (40 Gy in 15 fractions)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Early radiotherapy
Number of subjects: 308
Study: 2465949

Group type: EXPERIMENTAL
Intervention: PGI2 (5 ng/kg/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGE1 (25 ng/kg/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CG 4203 (25 ng/kg/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iloprost (1 and 2 ng/kg/min)
Number of subjects: 0
Study: 30507958

Group type: EXPERIMENTAL
Intervention: Active VR application
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Passive VR application
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 50
Study: 27716865

Group type: EXPERIMENTAL
Intervention: Low intensity physical activity (LIPA) - 2.5 hours of prolonged sitting with 2-minute bouts of walking every 20 minutes
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (CON) - 2.5 hours of prolonged sitting
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both LIPA and CON
Number of subjects: 14
Study: 26431252

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth (group 1)
Number of subjects: 180

Group type: COMPARATOR
Intervention: BCG vaccination at 34 weeks post conception age (group 2)
Number of subjects: 180
Study: 23629985

Group type: EXPERIMENTAL
Intervention: Medial arch orthosis (n=55)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Analgesics (control group, n=26)
Number of subjects: 81
Study: 21586313

Group type: EXPERIMENTAL
Intervention: Trace conditioning with contingency awareness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delay conditioning with contingency awareness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trace conditioning without contingency awareness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delay conditioning without contingency awareness
Number of subjects: 0
Study: 19322104

Group type: EXPERIMENTAL
Intervention: Iron-folic acid supplementation
Number of subjects: 1444

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 1444

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 1444
Study: 16860062

Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI) with magnifying endoscopy
Number of subjects: 63